[go: up one dir, main page]

ATE234092T1 - 2-alkylpyrrolidine - Google Patents

2-alkylpyrrolidine

Info

Publication number
ATE234092T1
ATE234092T1 AT96928360T AT96928360T ATE234092T1 AT E234092 T1 ATE234092 T1 AT E234092T1 AT 96928360 T AT96928360 T AT 96928360T AT 96928360 T AT96928360 T AT 96928360T AT E234092 T1 ATE234092 T1 AT E234092T1
Authority
AT
Austria
Prior art keywords
alkylpyrrolidine
methylpyrrolidines
hydroxymethylpyrrolidine
dihydroxy
diabetes
Prior art date
Application number
AT96928360T
Other languages
English (en)
Inventor
Karsten Lundgren
Palle Jakobsen
Marit Kristiansen
Leif Norskov-Lauritsen
Lars Narum
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Application granted granted Critical
Publication of ATE234092T1 publication Critical patent/ATE234092T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
AT96928360T 1995-09-08 1996-09-06 2-alkylpyrrolidine ATE234092T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK99295 1995-09-08
PCT/DK1996/000373 WO1997009040A1 (en) 1995-09-08 1996-09-06 2-alkylpyrrolidines

Publications (1)

Publication Number Publication Date
ATE234092T1 true ATE234092T1 (de) 2003-03-15

Family

ID=8099807

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96928360T ATE234092T1 (de) 1995-09-08 1996-09-06 2-alkylpyrrolidine

Country Status (12)

Country Link
US (2) US5854272A (de)
EP (3) EP1040827A3 (de)
JP (2) JP3043430B2 (de)
CN (1) CN1202105A (de)
AT (1) ATE234092T1 (de)
AU (1) AU724003B2 (de)
CZ (1) CZ120398A3 (de)
DE (1) DE69626660T2 (de)
HU (1) HUP9901132A2 (de)
IL (1) IL124109A (de)
NO (1) NO982055D0 (de)
WO (1) WO1997009040A1 (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1202105A (zh) * 1995-09-08 1998-12-16 诺沃挪第克公司 2－烷基吡咯烷化合物
US5952363A (en) * 1997-03-04 1999-09-14 Novo Nordisk A/S Pyrrolidine compounds useful in the treatment of diabetes
AU6291098A (en) * 1997-03-07 1998-09-29 Novo Nordisk A/S Novel heterocyclic compounds
AU2535700A (en) * 1999-02-12 2000-08-29 Novo Nordisk A/S Use of pyrrolidine derivatives for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity or appetite regulation
DE60022172D1 (de) * 1999-03-15 2005-09-29 Novo Nordisk As Salz des (2r,3r,4r)3,4-dihydroxy-2-hydroxymethylpyrrolidins
US6316489B1 (en) * 1999-03-15 2001-11-13 Novo Nordisk A/S Salt of (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine
US6239163B1 (en) 1999-03-15 2001-05-29 Novo Nordisk A/S Salt of (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine
ATE304998T1 (de) * 1999-03-15 2005-10-15 Novo Nordisk As Salz des (2r,3r,4r)-3,4-dihydroxy-2- hydroxmethylpyrrolidins
ATE378421T1 (de) * 1999-05-24 2007-11-15 Abaron Biosciences Inc Glycosyltransferase inhibitoren
US6043091A (en) * 1999-07-19 2000-03-28 Isis Pharmaceuticals Inc. Antisense modulation of liver glycogen phosphorylase expression
CO5271699A1 (es) 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
US6414163B1 (en) * 2000-08-02 2002-07-02 Board Of Trustees Of Michigan State University Process and intermediate compounds for the preparation of pyrrolidines
RU2374236C2 (ru) 2001-12-21 2009-11-27 Ново Нордиск А/С Амидные производные в качестве активаторов gk
GB0205176D0 (en) * 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
CA2744893A1 (en) 2002-06-27 2004-01-08 Novo Nordisk A/S Aryl carbonyl derivatives as glucokinase activators
WO2004037233A2 (en) * 2002-10-28 2004-05-06 Novo Nordisk A/S Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
US6960610B2 (en) 2002-10-28 2005-11-01 Novo Nordick, A/S Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
JP2007503453A (ja) 2003-05-14 2007-02-22 ノボ　ノルディスク　アクティーゼルスカブ 肥満症を治療するための新規化合物
JP4486792B2 (ja) * 2003-06-12 2010-06-23 学校法人近畿大学 環状オニウム化合物およびグルコシダーゼ阻害剤
AU2004275928B2 (en) 2003-09-30 2010-03-11 Novo Nordisk A/S Melanocortin receptor agonists
DE602004031455D1 (de) 2003-12-09 2011-03-31 Novo Nordisk As Regulierung der nahrungspräferenz mit glp-1-agonisten
CN102516240A (zh) 2004-01-06 2012-06-27 诺和诺德公司 杂芳基脲及其作为葡糖激酶活化剂的用途
WO2005105785A2 (en) 2004-05-04 2005-11-10 Novo Nordisk A/S Indole derivatives for treatment of obesity
WO2005120492A1 (en) 2004-06-11 2005-12-22 Novo Nordisk A/S Counteracting drug-induced obesity using glp-1 agonists
US20090298745A1 (en) * 2004-12-02 2009-12-03 Gerard Hugh Thomas Treatment of Diabetes with Glycogen Phosphorylase Inhibitors
AU2005311269B2 (en) 2004-12-03 2011-11-10 Transtech Pharma, Inc. Heteroaromatic glucokinase activators
KR100696187B1 (ko) 2005-05-03 2007-03-20 (주)리드젠 2-(2-아미노에틸)-1-메틸피롤리딘의 제조방법
WO2007006814A1 (en) 2005-07-14 2007-01-18 Novo Nordisk A/S Urea glucokinase activators
ATE523497T1 (de) 2006-11-15 2011-09-15 High Point Pharmaceuticals Llc Neue 2-(2-hydroxyphenyl)benzimidazole, die sich für die behandlung von obesitas und diabetes eignen
EP2099777B1 (de) 2007-01-11 2015-08-12 Novo Nordisk A/S Harnstoff-glucokinase-aktivatoren
WO2010049678A2 (en) * 2008-10-31 2010-05-06 Summit Corporation Plc Treatment of energy utilization diseases
JP5645137B2 (ja) * 2009-11-11 2014-12-24 国立大学法人富山大学 食後過血糖改善剤、およびピロリジン型イミノ糖またはその塩
WO2011104378A1 (en) 2010-02-26 2011-09-01 Novo Nordisk A/S Peptides for treatment of obesity
BR112012021231A2 (pt) 2010-02-26 2015-09-08 Basf Plant Science Co Gmbh método para acentuar o rendimento em plantas, planta, construto, uso de um construto, método para a produção de uma planta transgênica, partes coletáveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco e método para a produção de um produto
MX336412B (es) 2010-03-26 2016-01-19 Novo Nordisk As Nuevos analogos de glucagon.
CA2822493C (en) 2010-12-23 2018-11-20 Merck Sharp & Dohme Corp. Selective glycosidase inhibitors and uses thereof
MX2013011175A (es) 2011-03-28 2013-11-01 Novo Nordisk As Analogos de glucagon novedosos.
EP2691407B1 (de) 2011-03-31 2017-02-22 Alectos Therapeutics Inc. Selektive glycosidasehemmer und ihre verwendung
US9701693B2 (en) 2011-06-27 2017-07-11 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
RU2017101333A (ru) 2011-09-23 2018-12-19 Ново Нордиск А/С Новые аналоги глюкагона
US20150050371A1 (en) 2012-03-09 2015-02-19 Biotropics Malaysia Berhad Extract Formulations of Rhodamnia Cinerea And Uses Thereof
WO2014032185A1 (en) 2012-08-31 2014-03-06 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
WO2014032188A1 (en) 2012-08-31 2014-03-06 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
KR20150079711A (ko) 2012-10-31 2015-07-08 알렉토스 테라퓨틱스 인크. 글리코시다아제 저해제 및 이의 용도
RS59124B1 (sr) 2013-04-18 2019-09-30 Novo Nordisk As Stabilni, produženi koagonisti glp-1/glukagonskih receptora za medicinsku upotrebu
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
CN106349141B (zh) * 2016-08-30 2020-10-27 中国科学院化学研究所 多羟基吡咯烷类化合物及其制备方法和应用
WO2018167194A1 (en) 2017-03-15 2018-09-20 Novo Nordisk A/S Bicyclic compounds capable of binding to melanocortin 4 receptor
WO2019219714A1 (en) 2018-05-15 2019-11-21 Novo Nordisk A/S Compounds capable of binding to melanocortin 4 receptor
US20220184185A1 (en) 2018-07-25 2022-06-16 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
WO2020053414A1 (en) 2018-09-14 2020-03-19 Novo Nordisk A/S Bicyclic compounds capable of acting as melanocortin 4 receptor agonists

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1602744A (de) 1968-02-16 1971-01-18
JPS5346967A (en) 1976-10-08 1978-04-27 Kyowa Hakko Kogyo Co Ltd R-2-(beta-halogenoethyl)-1-methyl-pyrrolidine
JPS6058749B2 (ja) 1978-02-09 1985-12-21 日清製粉株式会社 光学活性ｎ‐メチル‐２‐ピロリジンエタノ−ルの製造法
JPS61118360A (ja) 1984-11-13 1986-06-05 Mitsubishi Chem Ind Ltd ピロリジン誘導体またはその塩
US4999360A (en) * 1987-12-21 1991-03-12 Monsanto Company Method of inhibiting virus
US4876268A (en) * 1988-11-03 1989-10-24 G. D. Searle & Co. Antiviral compounds and use thereof
US4973602A (en) * 1988-11-03 1990-11-27 G. D. Searle & Co. Antiviral compounds and a method of use thereas
ES2086323T3 (es) * 1988-11-03 1996-07-01 Searle & Co Derivados del didesoxi-arabinitol como compuestos antiviricos.
US4894388A (en) 1988-12-22 1990-01-16 Monsanto Company Glycosidase inhibitors and use thereof
EP0389723A1 (de) * 1989-03-29 1990-10-03 Merrell Dow Pharmaceuticals Inc. Alpha-glukosidase-Inhibitoren
FR2648486B1 (fr) * 1989-06-16 1991-08-30 Gerland Sa Composition pour le traitement antifeutrant de la laine
EP0422307A1 (de) * 1989-10-10 1991-04-17 Merrell Dow Pharmaceuticals Inc. Alpha-glukosidase-Schutzmittel
US5013842A (en) * 1990-01-22 1991-05-07 Monsanto Company Synthesis of chiral pyrrolidine and piperidine glycosidase inhibitors
US5290948A (en) * 1990-09-17 1994-03-01 Mcneilab, Inc. Process for producing polyhydroxylated piperidines and pyrrolidines and compounds thereof
US5401645A (en) 1992-03-16 1995-03-28 Monsanto Company Process for producing n-substituted polyhydroxy nitrogen-containing heterocycles utilizing acetobacteraceae and corynebacterium
JPH0625157A (ja) 1992-07-13 1994-02-01 Taisho Pharmaceut Co Ltd ポリヒドロキシピロリジン誘導体類およびその製造方法
CN1202105A (zh) * 1995-09-08 1998-12-16 诺沃挪第克公司 2－烷基吡咯烷化合物

Also Published As

Publication number Publication date
CN1202105A (zh) 1998-12-16
HUP9901132A2 (hu) 1999-07-28
WO1997009040A1 (en) 1997-03-13
AU724003B2 (en) 2000-09-07
NO982055L (no) 1998-05-06
JP2000095686A (ja) 2000-04-04
AU6785996A (en) 1997-03-27
EP1040827A2 (de) 2000-10-04
NO982055D0 (no) 1998-05-06
US5854272A (en) 1998-12-29
US6451836B1 (en) 2002-09-17
EP0884050A1 (de) 1998-12-16
IL124109A0 (en) 1998-12-06
EP0858335A1 (de) 1998-08-19
EP0858335B1 (de) 2003-03-12
EP1040827A3 (de) 2000-10-11
JPH11503762A (ja) 1999-03-30
JP3043430B2 (ja) 2000-05-22
DE69626660D1 (en) 2003-04-17
DE69626660T2 (de) 2003-08-21
IL124109A (en) 2001-10-31
CZ120398A3 (cs) 1998-12-16

Similar Documents

Publication Publication Date Title
ATE234092T1 (de) 2-alkylpyrrolidine
EA199800857A1 (ru) Композиция для снятия боли и способ снятия боли
ES2149268T3 (es) Procedimiento de estabilizacion de bebidas.
TR200100922T2 (tr) Aktif maddelerin akciğerler yolu ile tatbik edilmesi.
FR2715847B1 (fr) Composition contenant des acides nucléiques, préparation et utilisations.
ES2159318T3 (es) Inhibidores de la proteina quinasa c.
MXPA02004666A (es) Gelatinas recombinantes.
BG102644A (en) Improved concentrated inoculation and infusion solutions for intravasal application
DE59807248D1 (de) Implantatkörper
FI923680L (fi) Foerfarande foer framstaellning av (2r,3r) cis-b-fenylglysidinsyra
MX9101958A (es) Inhibidores de acat de urea de aminosulfonilo
NO963526D0 (no) N-metyl-N-[(1S)-1-fenyl-2-((3S)-3-hydroksypyrrolidin-1-yl)-etylÅ-2,2-difenylacetamid
DK0638068T3 (da) Fremgangsmåde til fremstilling af (S)-3-amino-1-substitueret-pyrrolidiner
ES2195655T3 (es) Procedimiento para tratar fiebre hemorragica virica con proteina c.
ID16192A (id) Proses pembuatan asam-asam .alpha., beta-karboksilat organik tak jenuh
ES2172682T3 (es) Preparaciones desodorantes con contenido en quitosano, clorohidrato de aluminio e inhibidores de esterasa.
NO990849L (no) Substituerte 1,2,3,4-tetrahydro-2-dibenzofuranaminer og 2-aminocyklohepta (b) benzofuraner
NO20005548L (no) Mykobakterieinhibitorer
PT633928E (pt) Microrganismos processo de preparacao e utilizacao
MXPA04010915A (es) Base y procedimiento de conocimiento de recursos humanos dinamicos.
TR200103219T2 (tr) Nöropatik ağrının iyileştirilmesinde kullanım için aroil aminoasil piroller
ES2175842T3 (es) Antagonistas de kv2.1.
DE69409961D1 (de) Triarylethylenderivate zur therapeutischen verwendung
IT1290910B1 (it) 2-amminotetralina otticamente attiva, procedimento per la sua preparazione e composizioni farmaceutiche che la contengono, attive
MY140504A (en) Statin-mmp inhibitor combinations

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties